Xinmaide Closes Nearly 300 Million Yuan Series B Funding Round

Nearly 300 Million Yuan Series B Secured as Drug Delivery Sector Attracts Fresh Capital

Chinese drug delivery company Xinmaide recently announced the completion of a nearly 300 million yuan Series B funding round. The round was led by Suzhou Industrial Park-based Oriza Seed, with follow-on investments from existing shareholders Hongyuan Capital and Dahua Venture Capital, alongside participation from Jinyugroup, Changshu Economic Development Holdings Fund of Funds, and Changshu Guofa Venture Capital.

The successful closing of this round signals strong capital market confidence in Xinmaide's technological capabilities and commercialization prospects in the drug delivery space.

Focused on Advanced Drug Delivery with Multi-Directional Platform Development

Following the funding, Xinmaide plans to continue building delivery technology platforms for innovative drugs, centered on pulmonary delivery, nasal delivery, and other advanced drug delivery approaches. The company aims to further strengthen its comprehensive capabilities in original R&D, precision engineering, industrialization, and global collaboration.

Drug delivery technology is a critical component of the modern pharmaceutical industry, directly impacting drug bioavailability, therapeutic efficacy, and patient compliance. In recent years, non-injection delivery routes such as inhaled formulations and nasal sprays have demonstrated unique advantages in treating respiratory and central nervous system diseases, underscoring the growing value of related technology platforms.

Strong Investor Lineup with Continued Backing from Existing Shareholders

Notably, existing shareholders Hongyuan Capital and Dahua Venture Capital chose to participate again in this round, reflecting their firm confidence in Xinmaide's long-term development. Lead investor Oriza Seed, a prominent venture capital firm under Suzhou Industrial Park, brings extensive investment experience and industry resources in the biopharmaceutical sector, and its involvement is expected to deliver significant strategic synergies for Xinmaide.

The participation of regional industry capital including Jinyugroup, Changshu Economic Development Holdings Fund of Funds, and Changshu Guofa Venture Capital also reflects local government recognition of and support for drug delivery as a high-end manufacturing niche.

Broad Prospects for the Drug Delivery Sector

The global drug delivery market is currently in a period of rapid growth. As novel therapies such as biologics and nucleic acid drugs continue to emerge, demand for efficient and precise delivery technologies keeps rising. In particular, with AI technology increasingly penetrating the pharmaceutical industry, intelligent drug design and delivery optimization are becoming key trends shaping the sector's future.

As a domestic company deeply rooted in drug delivery, Xinmaide is well-positioned to capture opportunities in this space through its core competencies in precision engineering and delivery technology. The injection of nearly 300 million yuan from this round will provide solid financial backing for its R&D and industrialization efforts, helping the company strengthen its competitive standing in the global market.